Evidence map›Paper›PMID 36298442›Full record

ArticleVaccines2022

A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy.

Christopher Robinson, Janine Oberye, Josephine van Boxmeer, Jessica D Albano, Hugh Tilson, Anthony Scialli, John A Vanchiere, Ellis Ides, Daphne Sawlwin, Matthew Hohenboken and 1 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Summary of the National Advisory Committee on Immunization (NACI) Updated Guidance on Influenza Vaccination During Pregnancy.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Christopher RobinsonCharleston Maternal Fetal Medicine, Summerville, SC 29485, USA.
Janine OberyeSeqirus Netherlands B.V., 1105 BJ Amsterdam, The Netherlands.
Josephine van BoxmeerSeqirus Netherlands B.V., 1105 BJ Amsterdam, The Netherlands.
Jessica D AlbanoSyneos Health, Wilmington, NC 28403, USA.
Hugh TilsonGillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA.
Anthony ScialliScialli Consulting LLC, Washington, DC 20008, USA.ORCID 0000-0003-1351-4572
John A VanchiereLSU Health Science Center, Shreveport, LA 71106, USA.
Ellis IdesSeqirus Netherlands B.V., 1105 BJ Amsterdam, The Netherlands.
Daphne SawlwinSeqirus Australia Pty Ltd., Parkville, VIC 3052, Australia.
Matthew HohenbokenSeqirus USA Inc., Cambridge, MA 02139, USA.
Jonathan EdelmanSeqirus USA Inc., Summit, NJ 07901, USA.
Seqirus (United States) · USLouisiana State University Health Sciences Center Shreveport · USSyneos Health (United States) · USUniversity of North Carolina at Chapel Hill · US

Funding

Seqirus Inc N/A
6 · The paper itself

Abstract

This US-based, prospective observational cohort study evaluated the safety of a quadrivalent inactivated influenza vaccine (IIV4; Afluria Quadrivalent) in pregnant persons immunized over four influenza seasons between 2017 and 2021. Pregnancy outcomes included live birth, stillbirth, spontaneous abortion, and elective termination. Infant events of interest were major congenital malformations (MCMs), preterm birth (<37 weeks gestational age), and low birth weight (LBW). Data were descriptive; prevalence point estimates were reported with 95% confidence intervals (CI). A total of 483 pregnant persons were given IIV4 and evaluated; 477 (98.8%) reported a live birth, and there were 2 stillbirths, 4 spontaneous abortions, and no elective terminations or maternal deaths. The prevalence rates of infant events were as follows: preterm birth, 7.2% (upper 95% CI, 9.6%); LBW, 5.4% (upper 95% CI, 7.4%); and MCMs, 0.8% (upper 95% CI, 1.9%). Point estimates and upper 95% CIs of the observed prevalence rates were lower than or similar to background prevalence in the general US population. Our findings suggest no evidence of a safety concern with vaccinating this group at high risk of influenza complications and are consistent with published data from databases and surveillance systems that monitor the safety of influenza vaccines in pregnant persons.

Indexed as

influenza vaccinationlow birthweightmajor congenital malformationspreterm birthspontaneous abortionstillbirth

Identifiers

PMID36298442
PMCPMC9611467
OpenAlexW4296828032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.